Array Biopharma Inc (NASDAQ:ARRY) has today come forward to announce that Shalini Sharp, the Chief Financial Officer who is at the same time Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)’s Executive Vice President move to work with the provider’s Board of Directors.
This happened in April 27, 2017 and according to close sources, the entry spells a lot of good things in future for this company. She will most probably be a part of the board’s Audit Committee and this comes in a wake when the company is doing all within it means to revamp its services.
The new top executive has worked in different companies and helped push them a notch higher in terms of business success. For instance, she will be remembered for her good work at Ultragenyx, which is of course a biopharmaceutical provider that majorly deals in coming up with top solutions to help face out rare diseases.
For an elongated period time, Ms. Sharp has led the corporate finance, information technology functions and the strategy section and that added to her experience in serving as a member of the company’s executive leadership team is for sure a huge deal for any company dealing in providing related services. It is for sure great news that she is actually moving into the life sciences industry bringing about some twenty years working experience.
The Chief Executive Officer of Array, Ron Squarerin making a statement said, “Shalini has an ideal background to complement the expertise of our Board of Directors. Her financial leadership at healthcare organizations will be invaluable as we focus our efforts in oncology and prepare for commercialization.”
When it came to Ms. Sharp turn to speak, she should her great excitement in being given the honor to work for the top provider. She proceeded, “Array has built an impressive development pipeline of therapeutics that is advancing in late-stage clinical trials and provides the opportunity to significantly benefit patients in areas of unmet need. I’m excited to join the company’s Board at such an important time in its history, as it nears commercialization of its drugs. I look forward to working with Ron and my fellow Board members through this important evolution of Array.”
There is much hope that the new leader will help the company make tremendous steps forward. However, this is just something we have to wait and see.